McChrystal Group competitors

Jim Roth serves as chief executive officer of Huron. He is a founding member of the company and has more than 38 years of experience working with the premier research universities, academic health centers, healthcare organizations and nonprofit research institutions across the U.S. and abroad.

Ben Williams is the Chief Executive Officer and Managing Partner of Spencer Stuart. Previously, Ben led the firm’s North American business, and prior to that served as the leader of Spencer Stuart's North American Financial Services Practice. In addition to his leadership responsibilities, Ben regularly advises clients on a variety of board and executive leadership recruiting, succession and culture related matters. Prior to joining Spencer Stuart, Ben spent 25 years in the financial services industry, most recently serving as President of the Investment Banking and Capital Markets Broker-Dealer of Wachovia, the nation’s 4th largest banking institution at the time. As Head of Wachovia’s Global Markets and Investment Banking division, Ben led the company's fixed income and equity sales, trading, and research activities, as well as investment banking, capital markets, corporate banking and commercial real estate. Ben was responsible for a $200 billion balance sheet, more than 5,000 employees worldwide, and was directly involved in the recruiting, hiring and on-boarding of many of the company's senior leaders. Ben also served as a member of Wachovia's corporate operating committee, asset liability committee, corporate diversity committee, and as a management representative to the risk committee of Wachovia's Board of Directors.

Build and manage Family Practice clinics aimed at serving the Hispanic population. Specialties: Entrepreneurship Supply Chain Management Corporate Growth Strategy

Carmine has served as our President and Chief Executive Officer and on our board of directors since October 2018. Previously, he served as President and Chief Executive Officer of Avelas Biosciences, Inc. from January 2014 to October 2018, where he has also served on the board of directors since January 2014 and as Chief Business from May 2012 to January 2014. Before that he served as Senior Vice President, Business Development for COI Pharmaceuticals, Inc. from May 2013 to October 2018, where he helped co-found five new biotechnology companies. Mr. Stengone also served as Vice President of Corporate Development for Afraxis, Inc. from 2010 to 2013 and co-founder and CEO of Araxes, Inc., a spin-out company from Araxes Holdings, Inc. from 2013 to 2014. Before that, he was with Phenomixs Corporation as the Senior Director of Business Development from 2006 to 2010, and previously held positions of increasing responsibility at Anadys Pharmaceuticals, Inc., from 2004 to 2006 and Johnson & Johnson Pharmaceutical Research and Development from 2003 to 2004. Carmine received his MBA from the Johnson Graduate School of Management at Cornell University in 2003. He also received an M.S. degree in Organic Chemistry from Duke University in 1999 and a B.S. in Chemistry from Wake Forest University in 1997.